The combined company will operate under the Spinal Stabilization Technologies name and be listed on the stock exchange. Spinal Stabilization Technologies is known for its lumbar intervertebral disc nucleus replacement device.
The deal is expected to close in the fourth quarter of 2023 or in early 2024. The company would have an estimated $302 million enterprise value post-transaction.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.